Advanced Glycation End Products Associated With Cardiometabolic Biomarkers in Treated Human Immunodeficiency Virus Infection.
Advanced Glycation End Products Associated With Cardiometabolic Biomarkers in Treated Human Immunodeficiency Virus Infection.
复制标题
DOI：
10.1093/ofid/ofab423
复制
发表时间：
2021-10
影响因子：
4.2
通讯作者：
McComsey GA
中科院分区：
文献类型：
--
作者：
El Kamari V;Rodriguez K;Moser C;Currier JS;Kelesidis T;Stein JH;Brown TT;Howell SK;Beisswenger PJ;McComsey GA
尽管抗逆转录病毒治疗(ART)取得了进展，但与未感染艾滋病毒的人相比，人类免疫缺陷病毒(HIV)感染者发生心脏代谢并发症的风险仍在增加。晚期糖基化终末产物(AGEs)与普通人群心脏代谢并发症的发生和发展有关。它们在艾滋病毒中的作用尚不清楚。ACTG A5260S是一项前瞻性的开放标签随机试验，在该试验中，艾滋病病毒携带者被随机分为替诺福韦富马酸异丙酯/恩曲他滨联合阿扎那韦/利托那韦、达鲁那韦/利托那韦或雷替格雷，为期96周。用线性回归分析血清AGEs与颈动脉内中膜厚度(CIMT)、内脏和皮下脂肪组织、总脂肪、瘦体重、体重指数、胰岛素抵抗、瘦素和脂联素的关系。总体而言，214名参与者包括在内。90%为男性，48%为白人，中位年龄为36岁，HIV-1RNA中位数为4.58log10拷贝/毫升，中位数为338个/微升。大多数年龄在ART开始96周后保持相对不变，除了甲乙二醛衍生的氢咪唑酮1(MG-H1)，在ART 96周后增加(平均倍数变化，1.15[95%可信区间，1.02-1.30])。在ART方案中没有检测到差异。即使在调整了临床相关因素后，随着时间的推移，年龄水平的增加也与身体脂肪组成指标恶化、胰岛素抵抗和CIMT相关。接受抗逆转录病毒治疗后，年龄水平没有下降。除MG-H1增加外，大多数年龄水平保持稳定。在接受抗逆转录病毒治疗的艾滋病毒携带者中，随着时间的推移，循环AGE的积累似乎与心脏代谢生物标志物的恶化独立相关。摘要：抗逆转录病毒疗法(ART)似乎不能有效降低晚期糖基化终末产物(AGE)水平。相反，在艺术启蒙之后，年龄水平似乎会增加。研究发现，在接受治疗的艾滋病毒携带者中，AGEs的积累与心脏代谢并发症独立相关。
Despite advances in antiretroviral therapy (ART), people living with human immunodeficiency virus (HIV) continue to be at increased risk of cardiometabolic complications compared to HIV-uninfected individuals. Advanced glycation end products (AGEs) are implicated in the development and progression of cardiometabolic complications in the general population. Their role in HIV remains unclear. ACTG A5260s is a prospective open-label randomized trial in which ART-naive people living with HIV were randomized to tenofovir disoproxil fumarate /emtricitabine plus atazanavir/ritonavir, darunavir/ritonavir, or raltegravir over 96 weeks. Changes in circulating AGEs with ART initiation were assessed, and linear regression was used to examine the associations between serum AGEs with carotid intima-media thickness (cIMT), visceral and subcutaneous adipose tissue, total fat, lean mass, body mass index, insulin resistance, leptin, and adiponectin. Overall, 214 participants were included. Ninety percent were male, 48% were White, the median age was 36 years, median HIV-1 RNA was 4.58 log10 copies/mL, and median CD4 count was 338 cells/µL. Most AGEs remained relatively unchanged following 96 weeks of ART initiation, except for methylglyoxal-derived hydroimidazolone 1 (MG-H1), which increased following 96 weeks of ART (mean fold change, 1.15 [95% confidence interval, 1.02–1.30]). No differences were detected across ART regimens. Increases in AGE levels over time were associated with worsening body fat composition measures, insulin resistance, and cIMT, even after adjusting for clinically relevant factors. AGE levels did not decrease following ART initiation. Most AGE levels remained stable, except for MG-H1, which increased. In people with HIV on ART, the accumulation of circulating AGEs over time appears to be independently associated with worsening cardiometabolic biomarkers. Summary: Antiretroviral therapy (ART) does not appear to be effective in reducing advanced glycation end product (AGE) levels. On the contrary, AGE levels seem to increase following ART initiation. Accumulation of AGEs was found to be independently associated with cardiometabolic complications in treated people living with HIV.
登录
查看更多内容
氧化的脂蛋白与HIV-1感染中炎症和免疫激活的标记有关。
DOI：
10.1097/qad.0000000000001238
发表时间：
2016-11-13
期刊：
AIDS (London, England)
影响因子：
--
作者：
Kelesidis T;Jackson N;McComsey GA;Wang X;Elashoff D;Dube MP;Brown TT;Yang OO;Stein JH;Currier JS
通讯作者：
Currier JS
影响因子：
4.6
作者：
Hileman CO;Funderburg NT
通讯作者：
Funderburg NT
影响因子：
6.4
作者：
Brown, Todd T.;Moser, Carlee;McComsey, Grace A.
通讯作者：
McComsey, Grace A.
影响因子：
4.6
作者：
Arakawa S;Suzuki R;Kurosaka D;Ikeda R;Hayashi H;Kayama T;Ohno RI;Nagai R;Marumo K;Saito M
通讯作者：
Saito M
影响因子：
29
作者：
Chaudhuri J;Bains Y;Guha S;Kahn A;Hall D;Bose N;Gugliucci A;Kapahi P
通讯作者：
Kapahi P